Sarepta Initiates FDA Dialogue on PMO Approvals Amid Lingering Regulatory Risk

What happened

Sarepta's PMO drugs, AMONDYS 45 and VYONDYS 53, face heightened regulatory scrutiny after the ESSENCE confirmatory trial missed statistical significance, putting their accelerated approvals at risk under FDORA expedited withdrawal procedures. The company has now requested a meeting with the FDA to discuss submitting supplemental new drug applications for full approval, a move framed as proactive but rooted in necessity to protect its nearly $1 billion annual PMO revenue base. This step aligns with Sarepta's disclosed strategy to engage regulators post-ESSENCE, yet filings explicitly warn that FDA actions could still include label changes, revocation, or market removal, reflecting deep uncertainty. The FDA's response will be a critical monitor, as the DeepValue report identifies accelerated-approval withdrawal for these drugs as a key thesis breaker that could trigger a bear-case scenario with a $10 implied value. While this update shows Sarepta is actively managing regulatory peril, it does not resolve the underlying fragility that keeps the investment thesis on hold, emphasizing that real progress depends on FDA receptiveness and tangible outcomes.

Implication

Sarepta's request for an FDA meeting on PMO sNDAs is a defensive move to preempt potential accelerated-approval withdrawals, yet it fails to eliminate the 30% probability bear scenario where such actions could crush revenue and drive the stock toward $10. Investors should interpret this as part of a protracted regulatory process that could either stabilize the PMO cash engine or exacerbate downside risks, maintaining the WAIT rating's relevance until evidence of FDA cooperation or improved ELEVIDYS performance justifies entry. The development adds a near-term catalyst but does not alter the fundamental risk profile dominated by binary FDA outcomes and operational volatility, as highlighted in the report's base-case reliance on infusion throughput improvements. Consequently, any positive market reaction should be viewed skeptically, with position sizing remaining minimal to avoid asymmetric exposure to regulatory setbacks. Overall, this reinforces the analytical stance that Sarepta's equity is a speculative play requiring patience for observable progress rather than speculative optimism.

Thesis delta

This news represents a tactical step by Sarepta to address the PMO regulatory overhang, but it does not shift the core thesis that the stock remains event-driven with high downside risk from FDA actions. The incremental development highlights ongoing engagement but lacks concrete resolution, meaning investors should still wait for clearer FDA feedback or improved ELEVIDYS cadence before reconsidering the WAIT rating.